Creating Regulatory Pathways for Personalized & Oncology-Focused mRNA Therapies in a Framework Built for Vaccines

• Understanding how personalized and patient-specific mRNA products are being approached by EMA and MHRA
• Learning from ongoing oncology-focused mRNA trials navigating the current patchwork of global expectations
• Discussing gaps in guidance for non-infectious mRNA indications and how companies are addressing them

Speakers:

Ruben Rizzi

Senior Vice President - Global Regulatory Affairs, Safety & Pharmacovigilance

BioNTech